Cell Growth & Differentiation, Vol 5, Issue 10 1127-1135, Copyright © 1994 by American Association of Cancer Research

ARTICLES

Functional characterization of two cholecystokinin-B/gastrin receptor isoforms: a preferential splice donor site in the human receptor gene

M Ito, N Iwata, T Taniguchi, T Murayama, K Chihara and T Matsui
Department of Medicine, Kobe University School of Medicine, Japan.

The cholecystokinin-B and gastrin receptor is encoded by a single gene composed of five exons and spanning over 10 kilobases on human chromosome 11p 15.5-->15.4. Exon 4 has two possible alternative splicing donor sites that seem to be conserved in other species such as the canine, rat, Mastomys, and mouse. They could generate two receptor isoforms (short- and long-form), which differ in their putative third cytoplasmic domain of the serpentine G-protein-coupled receptors. In the present study, we examined whether an alternative splicing is operated in a tissue-specific manner and whether two receptor isoforms have functional differences. RNase-protection assay and S1 nuclease mapping demonstrated the preferential expression of the short-form in the human brain as well as the digestive organs, stomach and pancreas. The two putative isoforms of the cholecystokinin-B/gastrin receptor expressed in mouse fibroblasts showed the same characteristics in their ligand-bindings, the major signal transduction such as phosphoinositides production, cytoplasmic Ca2+ increase, tyrosine phosphorylation of focal adhesion kinase, activation of mitogen-activated protein kinase, and the induction of early-responsive genes such as c-fos, c-myc, and c-jun. Moreover, the ligand-dependent trophic effect was seen in both receptor isoforms. Taken together with the absence of tissue-specific expression of two receptor isoforms, these results suggest a species-specific dominant splice donor site in exon 4 of the human receptor gene.

This article has been cited by other articles:

				M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF]

				L. Aloj, C. Caraco, M. Panico, A. Zannetti, S. Del Vecchio, D. Tesauro, S. De Luca, C. Arra, C. Pedone, G. Morelli, et al. In Vitro and In Vivo Evaluation of 111In-DTPAGlu-G-CCK8 for Cholecystokinin-B Receptor Imaging J. Nucl. Med., March 1, 2004; 45(3): 485 - 494. [Abstract] [Full Text]

				M. Laverdiere, J. Beaudoin, and A. Lavigueur Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene Nucleic Acids Res., March 15, 2000; 28(6): 1489 - 1497. [Abstract] [Full Text] [PDF]

				S A Watson, T M Morris, A Varro, D Michaeli, and A M Smith A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth Gut, December 1, 1999; 45(6): 812 - 817. [Abstract] [Full Text] [PDF]

				F. Noble, S. A. Wank, J. N. Crawley, J. Bradwejn, K. B. Seroogy, M. Hamon, and B. P. Roques International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors Pharmacol. Rev., December 1, 1999; 51(4): 745 - 781. [Abstract] [Full Text] [PDF]

				D F McWilliams, S A Watson, D M Crosbee, D Michaeli, and R Seth Coexpression of gastrin and gastrin receptors (CCK-B and Delta CCK-B) in gastrointestinal tumour cell lines Gut, June 1, 1998; 42(6): 795 - 798. [Abstract] [Full Text] [PDF]

				C. Oiry, D. Gagne, E. Cottin, N. Bernad, J.-C. Galleyrand, G. Bergé, M.-F. Lignon, P. Eldin, M. Le Cunff, J. Léger, et al. CholecystokininB Receptor from Human Jurkat Lymphoblastic T Cells Is Involved in Activator Protein-1-Responsive Gene Activation Mol. Pharmacol., August 1, 1997; 52(2): 292 - 299. [Abstract] [Full Text]